Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7337751

N=C(N)c1ccc2cccc(NC(=O)COCc3ccccc3)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.65
F2 P00734 9/20 0.46
TMPRSS6 Q8IU80 6/20 0.46
PLG P00747 2/20 0.44
PLAT P00750 2/20 0.44
KLK1 P06870 2/20 0.44
F9 P00740 2/20 0.42
F10 P00742 1/20 0.42
TRPV1 Q8NER1 2/20 0.41
PRSS1 P07477 1/20 0.41
CSNK1D P48730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7456113 0.83 PLAU (0.63) PLAUF2TMPRSS6PLGPLAT
Trifluoroacetic Acid SCHEMBL7337767 0.82 PLAU (0.43) PLAUTRPV1CSNK1D
Trifluoroacetic Acid SCHEMBL7343433 0.82 PLAU (0.63) PLAUF2TMPRSS6PLGPLAT
Trifluoroacetic Acid SCHEMBL7340769 0.79 PLAU (0.64) PLAUF2TMPRSS6PLGPLAT
SCHEMBL7334054 0.78 PLAU (0.73) PLAUF2PLGPLATKLK1
SCHEMBL7337763 0.77 PLAU (0.61) PLAUF2TMPRSS6PLGPLAT
Trifluoroacetic Acid SCHEMBL7340225 0.77 PLAU (0.54) PLAUF2TMPRSS6PLGPLAT
SCHEMBL7335327 0.76 PLAU (0.72) PLAUF2PLGPLATKLK1
SCHEMBL7344902 0.75 PLAU (0.67) PLAUF2PLGPLATKLK1
SCHEMBL7335597 0.74 PLAU (0.74) PLAUF2PLGPLATKLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885TMPRSS6 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.